MissionIR Articles
-
MissionIRNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Reaches Agreement Regarding Reorganization of Three US Subsidiaries
RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, has announced a prepackaged…
-
RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City
RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas, recently presented at the…
-
RVL Pharmaceuticals plc (NASDAQ: RVLP) Looking to Capitalize on UPNEEQ’s Significant Potential
RVL Pharmaceuticals (NASDAQ: RVLP), is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis (ptosis, or low-lying eyelids) in adults. The company believes…
-
MissionIRNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Anticipating Growing Demand for UPNEEQ(R)
RVL Pharmaceuticals (NASDAQ: RVLP) is a a specialty pharmaceutical company whose near-term focus is to continue the rollout of UPNEEQ(R) into the medical aesthetics market through its dedicated sales force. “UPNEEQ(R) is the first non-surgical…
-
RVL Pharmaceuticals plc (NASDAQ: RVLP) to Attend H.C. Wainwright 25th Annual Global Investment Conference and Discuss UPNEEQ(R) for Treating Acquired Blepharoptosis
RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company, recently announced that its CEO Brian Markison will be participating in a fireside chat and hosting 1-on-1 investor meetings during the H.C. Wainwright 25th Annual Global Investment…
-
MissionIRNewsBreaks – Why RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’
RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, available by prescription for the treatment of acquired blepharoptosis (low-lying eyelid(s)) in adults. “UPNEEQ(R) (‘RVL-1201’)…
-
RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’
RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, which is available by prescription for the treatment of acquired blepharoptosis, or low-lying eyelid(s), in…
Search Articles
Latest Articles
- MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline
- MissionIRNewsBreaks – Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Highlights $35M Program to Advance Alaska’s Upper Kobuk Mineral Projects
- GridAI Technologies Corp. (NASDAQ: GRDX) Is Capitalizing on the Data Center and AI-Driven Transformation of the Energy Sector
- LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) Provides Update on Samarium and Gadolinium Supply Initiative